ADDEX THERAPEUTICS SA | 5,245 Euro | +0,022 +0,42 % | |
| WKN: A0MSH6 ISIN: CH0029850754 Ticker-Symbol: APE | Stuttgart | 22.05.13 | 08:03 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 21.05. | ADX71441 on track for phase 1 testing, says Addex | 1 | StockMarketWire | |
| 21.05. | Addex Therapeutics: Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441 | 74 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B
Positive Allosteric modulator, ADX71441
. Processed and transmitted by Thomson Reuters ONE.
The issuer... Mehr lesen zu: Addex Therapeutics: Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441 | ||||
| 01.05. | Study reinforces dipraglurant data, says Addex | 3 | StockMarketWire | |
| 01.05. | Addex Therapeutics: Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study | 96 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor
Occupancy in a Non-Human Primate PET Study
. Processed and transmitted by Thomson Reuters ONE.
The issuer... Mehr lesen zu: Addex Therapeutics: Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human Primate PET Study | ||||
| 30.04. | Addex Therapeutics: Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role | 47 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of... Mehr lesen zu: Addex Therapeutics: Addex Announces CFO, Tim Dyer, to Transition to External Consulting Role | ||||
| 30.04. | Addex reveals positive data on alcoholism drug | 5 | StockMarketWire | |
| 30.04. | Addex Therapeutics: Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence | 64 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic
Alcohol Dependence
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible... Mehr lesen zu: Addex Therapeutics: Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence | ||||
| 24.04. | Addex gets approval for clinical trial | 3 | StockMarketWire | |
| 24.04. | Addex Therapeutics: Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441 | 73 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for
ADX71441
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for... Mehr lesen zu: Addex Therapeutics: Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441 | ||||
| 22.04. | Addex Therapeutics: Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant | 59 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Announces Issuance of a Broad European Composition of Matter Patent for
Dipraglurant
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible... Mehr lesen zu: Addex Therapeutics: Addex Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant | ||||
| 18.04. | Addex Therapeutics: Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) | 53 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated
Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1)
. Processed and transmitted by... Mehr lesen zu: Addex Therapeutics: Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) | ||||
| 21.03. | Addex Therapeutics: Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN) | 78 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results
at the 2013 Annual Meeting of the American Academy of Neurology (AAN)
. Processed and transmitted... Mehr lesen zu: Addex Therapeutics: Addex Therapeutics Announces Presentation of Dipraglurant Phase 2a Study Results at the 2013 Annual Meeting of the American Academy of Neurology (AAN) | ||||
| 20.03. | Addex resolutions passed at AGM | 2 | StockMarketWire | |
| 20.03. | Addex wins $1m Michael J Fox Foundation grant for Parkinson's disease research | - | Pharma Bus Review | |
| 20.03. | Addex Therapeutics: Addex Shareholders Approve All Board Proposals at Annual General Meeting | 82 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Shareholders Approve All Board Proposals at Annual General Meeting
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of... Mehr lesen zu: Addex Therapeutics: Addex Shareholders Approve All Board Proposals at Annual General Meeting | ||||
| 19.03. | Addex gets $1m grant for Parkinson's drug testing | 2 | StockMarketWire | |
| 19.03. | Addex Therapeutics: Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research | 81 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for
Parkinson's Research
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible... Mehr lesen zu: Addex Therapeutics: Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research | ||||
| 04.03. | Addex agrees partnership deal with Viva Biotech | 11 | StockMarketWire | |
| 04.03. | Addex Therapeutics: Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor | 92 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting
Adenosine 2A Receptor
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible... Mehr lesen zu: Addex Therapeutics: Addex Partners with Viva Biotech to Advance Allosteric Modulators Targeting Adenosine 2A Receptor | ||||
| 28.02. | Addex Therapeutics: Addex Therapeutics Reports 2012 Financial Results | 88 | Thomson Reuters ONE | |
| Addex Therapeutics /
Addex Therapeutics Reports 2012 Financial Results
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement. 2012... Mehr lesen zu: Addex Therapeutics: Addex Therapeutics Reports 2012 Financial Results | ||||
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| SANTHERA | 1,62 | +8,65 % | Santhera: Aktionäre votieren für Fortführung der Geschäftstätigkeit |
| NOVARTIS | 57,86 | -0,10 % | Gericht prüft Klage von Pharmakonzern Novartis gegen Bewertung |
| BIOMARIN PHARMACEUTICAL | 50,25 | +2,38 % | BioMarin Pharmaceutical Inc. Presents at UBS Global Healthcare Conference, May-21-2013 09:00 AM |
| ACINO | 74,00 | +1,09 % | Acino erzielt 2012 einen Reingewinn von 9,4 Mio EUR |
| ROCHE | 200,30 | +1,08 % | S&P Equity hebt Ziel für Roche auf 265 Franken - 'Buy' |
